2024
Lesions to the mediodorsal thalamus, but not orbitofrontal cortex, enhance volatility beliefs linked to paranoia
Suthaharan P, Thompson S, Rossi-Goldthorpe R, Rudebeck P, Walton M, Chakraborty S, Noonan M, Costa V, Murray E, Mathys C, Groman S, Mitchell A, Taylor J, Corlett P, Chang S. Lesions to the mediodorsal thalamus, but not orbitofrontal cortex, enhance volatility beliefs linked to paranoia. Cell Reports 2024, 43: 114355. PMID: 38870010, PMCID: PMC11231991, DOI: 10.1016/j.celrep.2024.114355.Peer-Reviewed Original ResearchOrbitofrontal cortexMediodorsal thalamusReward learning rateAssociated with paranoiaExcitotoxic lesionsBrain regionsUnoperated monkeysAction selectionAdaptive behaviorParanoiaBelief updatingMDmcMeaningful changeCortexThalamusBeliefsLearning rateRobust to variabilityCompare performanceRewardBehaviorBrainMonkeysAction policiesPerception
1998
In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector
During M, Samulski R, Elsworth J, Kaplitt M, Leone P, Xiao X, Li J, Freese A, Taylor J, Roth R, Sladek J, O’Malley K, Redmond D. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Therapy 1998, 5: 820-827. PMID: 9747462, DOI: 10.1038/sj.gt.3300650.Peer-Reviewed Original ResearchMeSH Keywords1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsAromatic-L-Amino-Acid DecarboxylasesChlorocebus aethiopsDependovirusDopamineDopamine AgentsGene ExpressionGene Transfer TechniquesGenetic VectorsHumansImmunohistochemistryMaleParkinson DiseaseTrigeminal Caudal NucleusTyrosine 3-MonooxygenaseConceptsTyrosine hydroxylaseStriatal cellsDopamine-depleted monkeysAdeno-associated virus vectorProduction of dopamineParkinsonian monkeysTransient feverSevere hyperactivityStriatal dopaminePrimate neuronsStereotactic injectionHistological evidencePrimate modelInjection tractNeurotoxin MPTPDopamine productionParkinson's diseaseTreatment groupsSignificant toxicityBehavioral effectsVivo gene therapyElevated levelsBiochemical effectsFirst dayMonkeys
1994
Novel Radioligands for the Dopamine Transporter Demonstrate the Presence of Intrastriatal Nigral Grafts in the MPTP-Treated Monkey: Correlation with Improved Behavioral Function
Elsworth J, Al-Tikriti M, Sladek J, Taylor J, Innis R, Redmond D, Roth R. Novel Radioligands for the Dopamine Transporter Demonstrate the Presence of Intrastriatal Nigral Grafts in the MPTP-Treated Monkey: Correlation with Improved Behavioral Function. Experimental Neurology 1994, 126: 299-304. PMID: 7925828, DOI: 10.1006/exnr.1994.1068.Peer-Reviewed Original ResearchMeSH Keywords1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsAutoradiographyBrain Tissue TransplantationCarrier ProteinsChlorocebus aethiopsCocaineCorpus StriatumDopamine Plasma Membrane Transport ProteinsFetal Tissue TransplantationIodine RadioisotopesMaleMembrane GlycoproteinsMembrane Transport ProteinsNerve Tissue ProteinsParkinson Disease, SecondaryRadioligand AssaySerotonin Plasma Membrane Transport ProteinsSubstantia NigraTransplantation, HeterotopicTransplantation, HomologousConceptsCaudate nucleusFetal ventral mesencephalic cellsIntrastriatal nigral graftsVentral mesencephalic cellsAdult MPTPNigral graftsSerotonergic fibersTransplantation procedureMesencephalic cellsNovel radioligandNeurochemical identityDopamine transporterTransporter sitesSerotonin transporterBehavioral functionsMPTPCocaine analogMonkeysCocaine derivativePreliminary studyHigh affinityDopaminergicGraft
1991
The D1 receptor antagonist, SCH 23390, induces signs of parkinsonism in African green monkeys
Lawrence M, Redmond D, Elsworth J, Taylor J, Roth R. The D1 receptor antagonist, SCH 23390, induces signs of parkinsonism in African green monkeys. Life Sciences 1991, 49: pl229-pl234. PMID: 1836030, DOI: 10.1016/0024-3205(91)90299-q.Peer-Reviewed Original ResearchConceptsSCH 23390African green monkeysD1 antagonistHealthy African green monkeysGreen monkeysParkinsonian side effectsD1 receptor antagonistPoverty of movementSigns of parkinsonismSelective D1 antagonistFull D1 agonistParkinsonian signsReceptor antagonistD1 agonistD1 receptorsSystemic administrationParkinson's diseasePsychiatric disordersSide effectsMotor changesClinical useParkinsonismAntagonistBlink rateMonkeys